Dragon Pharmaceutical Inc. is an international biopharmaceutical corporation engaged in the discovery, development and commercialization of genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, Dragon believes that it has become one of the world’s most competitive producers of Erythropoietin (EPO) a breakthrough drug that has revolutionized the treatment of anemia. Dragon is also applying its platform technology to the development of other generic and novel protein drugs.
EuroSciCon, founded in 2001 is a UK based independent life science Events Company with predominantly business and academic client base. The key strategic objective of EuroSciCon is to communicate science and medical research between academia, clinical practice and the pharmaceutical industry. Most of its events are in Europe and London or live streamed. EuroSciCon expanded its operations to international in association with Meetings International, Singapore. All major meetings of EuroSciCon and Meetings International are accredited with Continued Professional Education (CPD), Continued Education (CE), Continued Medical Education (CME) Credits.